“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Aakash Desai, MBBS, MPH; Ibiayi Dagogo-Jack, MD; and Patrick Forde, MBBCh, PhD, discuss how to decode the diagnosis of malignant pleural mesothelioma and review data to optimize frontline and subsequent treatment of this rare malignancy.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply a structured algorithm for patient evaluation, including selection of appropriate immunohistochemistry/ancillary tests, to accurately diagnose malignant pleural mesothelioma (MPM)
• Evaluate new evidence supporting frontline options and emerging therapies for MPM
• Integrate the latest data into personalized treatment plans based on patient characteristics
• Describe roles of the multidisciplinary care team in the collaborative management of MPM

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Chair:

Aakash Desai, MBBS, MPH​

Assistant Professor of Medicine
Hematology and Oncology​
O’Neal Cancer Center
University of Alabama at Birmingham​
Birmingham, AL

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, ConcertAI, Daiichi Sankyo, Foundation Medicine, Janssen Oncology, Lilly, Merus, Regeneron, Sanofi

Faculty:

Ibiayi Dagogo-Jack, MD​

Associate Professor of Medicine ​
Harvard Medical School​
Massachusetts General Hospital
Brigham Cancer Institute​
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bayer, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen, Merus, Novocure, Nuvalent, Pfizer, Roche, Thermo Fisher Scientific; Grant/Research Funding: Genentech, Novartis, Pfizer

Patrick Forde, MBBCh, PhD ​

Medical Oncologist​
Johns Hopkins University​
Baltimore, MD​
Trinity College ​
Dublin, Ireland

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, F-Star, Flame Biosciences, Fosun, G1, Genentech, iTeos Therapeutics, Janssen, Novartis, Regeneron, Sanofi, Surface, Synthekine, Tavotek, Teva; Grant/Research Funding: AstraZeneca, BioNTech, Bristol Myers Squibb, Regeneron, Summit

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the BAP1 cancer syndrome and surgical management of mesothelioma, go to https://www.gotoper.com/courses/d-is-for-diagnosis-decoding-a-difficult-thoracic-malignancypiecing-together-a-rare-diagnosis-preparing-for-tomorrows-treatments.

Release Date

February 12, 2026

Expiration Date

February 12, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.